Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network

G. Specchia, P. Pregno, M. Breccia, F. Castagnetti, C. Monagheddu, M. Bonifacio, M. Tiribelli, F. Stagno, G. Caocci, B. Martino, L. Luciano, M. Pizzuti, A. Gozzini, A.R. Scortechini, F. Albano, M. Bergamaschi, I. Capodanno, A. Patriarca, C. Fava, G. Rege-CambrinF. Sorà, S. Galimberti, M. Bocchia, G. Binotto, G. Reddiconto, P. DiTonno, A. Maggi, G. Sanpaolo, M.S. De Candia, V. Giai, E. Abruzzese, M.C. Miggiano, G. La Barba, G. Pietrantuono, A. Guella, L. Levato, O. Mulas, F. Saccona, G. Rosti, P. Musto, F. Di Raimondo, F. Pane, M. Baccarani, G. Saglio, G. Ciccone

Research output: Contribution to journalArticlepeer-review


An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 treated with imatinib (IMA) and 598 with 2nd generation tyrosine kinase inhibitors (2GTKI). IMA-treated patients were much older (median age 69 years, IQR 58-77) than the 2GTKI group (52, IQR 41-63) and had more comorbidities. Estimated 4-year overall survival of the entire cohort was 89% (95%CI 85.9-91.4). Overall, 73 patients (6.1%) died: 17 (2.8%) in the 2GTKI vs 56 (9.2%) in the IMA cohort (adjusted HR=0.50; 95% CI=0.26-0.94), but no differences were detected for CML-related mortality (10 (1.7%) vs 11 (1.8%) in the 2GTKIs vs IMA cohort (sHR=1.61; 0.52-4.96). The ELTS score was associated to CML mortality (high risk vs low, HR=9.67; 95%CI 2.94-31.74; p<0.001), while age (per year, HR=1.03; 95%CI 1.00-1.06; p=0.064), CCI (4-5 vs 2, HR=5.22; 95%CI 2.56-10.65; p<0.001), ELTS score (high risk vs low, HR=3.11; 95%CI 1.52-6.35, p=0.002) and 2GTKI vs IMA (HR=0.26; 95%CI 0.10-0.65, p=0.004) were associated to an increased risk of non-related CML mortality. The ELTS score showed a better discriminant ability than the Sokal score in all comparisons. © Copyright © 2021 Specchia, Pregno, Breccia, Castagnetti, Monagheddu, Bonifacio, Tiribelli, Stagno, Caocci, Martino, Luciano, Pizzuti, Gozzini, Scortechini, Albano, Bergamaschi, Capodanno, Patriarca, Fava, Rege-Cambrin, Sorà, Galimberti, Bocchia, Binotto, Reddiconto, DiTonno, Maggi, Sanpaolo, De Candia, Giai, Abruzzese, Miggiano, La Barba, Pietrantuono, Guella, Levato, Mulas, Saccona, Rosti, Musto, Di Raimondo, Pane, Baccarani, Saglio and Ciccone.
Original languageEnglish
JournalFrontiers in Oncology
Publication statusPublished - 2021


  • imatinib
  • protein tyrosine kinase inhibitor
  • adult
  • aged
  • Article
  • bioinformatics
  • cancer mortality
  • cancer prognosis
  • cardiovascular disease
  • cell death
  • chronic myeloid leukemia
  • cohort analysis
  • comorbidity
  • cytogenetics
  • end stage renal disease
  • female
  • gastrointestinal disease
  • gene sequence
  • heart function
  • homeostasis
  • hospitalization
  • human
  • hyperlipidemia
  • hypertension
  • intestine flora
  • leukemia
  • leukocyte count
  • lung disease
  • major clinical study
  • male
  • metabolic disorder
  • mortality
  • multicenter study
  • observational study
  • overall survival
  • prevalence
  • risk factor


Dive into the research topics of 'Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network'. Together they form a unique fingerprint.

Cite this